In this article, we will list the 5 High Growth Stocks to Buy and Hold for the Next Decade. Please visit 15 High Growth Stocks to Buy and Hold for the Next Decade if you would like to see the extended list and the methodology behind it.
5. Roivant Sciences Ltd. (NASDAQ:ROIV)
On May 21, 2026, TD Cowen raised the firm’s price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $41 from $38 and maintained a Buy rating on the shares. TD Cowen said IMVT-1402 toplined impressive Ph2b D2T RA data, with ACR20 of 73%, ACR50 of 55%, and ACR70 of 36%. The firm also said Roivant has many more catalysts ahead.
Citi also raised the firm’s price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $42 from $35 and maintained a Buy rating on the shares. Citi said it sees further upside from Roivant’s second half of 2026 data catalysts and kept the stock as a top pick following the IMVT-1402 data.
A day earlier, Roivant Sciences Ltd. (NASDAQ:ROIV) reported fiscal Q4 EPS of 28c, compared to the consensus estimate of (35c). Revenue totaled $2.52M, versus the consensus estimate of $3.91M. CEO Matt Gline said the positive Period 1 data from the IMVT-1402 trial in D2T RA showed “exciting potential” for a new treatment approach in RA patients who have failed multiple prior therapies. Gline also pointed to the FDA’s Breakthrough Therapy Designation for brepocitinib in cutaneous sarcoidosis and said the company expects several second-half 2026 updates, including brepocitinib’s expected launch in DM by the end of September and data in NIU, CLE, PH-ILD, and D2T RA.
Roivant Sciences Ltd. (NASDAQ:ROIV) focuses on the discovery, development, and commercialization of medicines and technologies.
4. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
On May 21, 2026, Bernstein analyst Jeffrey Walch initiated coverage of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) with an Outperform rating and a $221 price target. Walch said Neurocrine is one of the more promising investments within Bernstein’s initial coverage group of mid-cap biopharmaceutical companies, noting that the company’s two key medicines are already approved and have a long runway until loss-of-exclusivity. Bernstein added that upside exists to the current share price as the market gains more certainty around future market share and a potential positive Phase 3 trial readout.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced new data from a clinician survey on patients with mild tardive dyskinesia, or TD, and treatment with INGREZZA, or valbenazine, capsules in a real-world setting. In a subgroup analysis, nearly all patients with clinician-reported mild TD treated with INGREZZA had fewer uncontrolled movements, with most showing symptom improvement within four weeks. The findings were presented at the American Psychiatric Association 2026 Annual Meeting, held May 16-20 in San Francisco. The analysis was based on clinician survey data covering TD symptoms, functional impairment, and improvement after INGREZZA treatment. Before treatment, clinicians reported that mild TD movements affected functional status in 90% of patients and independence in 84% of patients. After INGREZZA was started, 86% of patients with improved uncontrolled movements showed improvement in four weeks or less. Clinicians also reported improvement in more than 90% of impacted patients across functional areas, including speech, dexterity, social status, emotional status, and activities of daily living.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) discovers, develops, and commercializes pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
3. American Healthcare REIT, Inc. (NYSE:AHR)
On May 22, 2026, BofA raised the firm’s price target on American Healthcare REIT, Inc. (NYSE:AHR) to $67 from $63 and maintained a Buy rating on the shares. BofA said it updated price targets on several REITs after reviewing its models.
On May 20, 2026, American Healthcare REIT, Inc. (NYSE:AHR) announced an underwritten public offering of 14M shares of common stock. The 14M-share spot secondary offering was priced at $50.40, below the prior closing price of $51.68. BofA Securities is acting as the underwriter for the offering.
Earlier in May, American Healthcare REIT, Inc. (NYSE:AHR) reported Q1 normalized FFO of 50c, ahead of the consensus estimate of 47c. Revenue totaled $650.77M, below the consensus estimate of $687.04M. CEO Jeff Hanson said the quarter reflected an “exceptionally strong period” across core metrics, including the company’s ninth consecutive quarter of double-digit Same-Store NOI growth, efficient capital formation and deployment, a strengthened balance sheet, and a raise to full-year 2026 Same-Store NOI growth and NFFO per share guidance.
American Healthcare REIT, Inc. (NYSE:AHR) owns and operates a diversified portfolio of clinical healthcare real estate across the U.S., U.K., and the Isle of Man.
2. Silicon Motion Technology Corporation (NASDAQ:SIMO)
On May 20, 2026, Silicon Motion Technology Corporation (NASDAQ:SIMO) announced that it achieved ISO 26262 functional safety process certification for automotive applications. The company said ISO 26262 sets requirements for the development and validation of automotive electrical and electronic systems, and said the certification reflects its investment in “automotive-grade engineering excellence” and support for safe, reliable storage technologies used in next-generation vehicles.
On May 12, 2026, B. Riley raised the firm’s price target on Silicon Motion Technology Corporation (NASDAQ:SIMO) to $312 from $250 and maintained a Buy rating on the shares. B. Riley said AI investment is accelerating faster than expected, with demand from hyperscalers and neo-cloud providers driving higher 2026-2028 capital expenditure estimates. The firm also cited tightening supply-demand fundamentals, strong semiconductor EPS revisions, and elevated sector valuations despite recent volatility.
Last month, Silicon Motion Technology Corporation (NASDAQ:SIMO) reported Q1 non-GAAP EPS of $1.58, compared to $1.26 in the last quarter. Revenue totaled $342.1M, compared to $278.5M in the previous quarter. President and CEO Wallace Kou said the results exceeded revenue, gross margin, and operating margin expectations, driven mainly by growth in embedded eMMC & UFS controllers and Ferri and boot drive solutions. Kou also said MonTitan will enter volume commercial production in the current quarter, earlier than planned, while customers expect to ramp five tier-one CSPs in the second half of the year.
Silicon Motion Technology Corporation (NASDAQ:SIMO) designs, develops, and markets NAND flash controllers for solid-state storage devices and related devices internationally.
1. NVIDIA Corporation (NASDAQ:NVDA)
On May 20, 2026, NVIDIA Corporation (NASDAQ:NVDA) CEO Jensen Huang said the company has “largely conceded” China’s AI chip market to Huawei as U.S. export restrictions continue reshaping the global semiconductor landscape. Speaking to CNBC’s Sara Eisen, Huang said demand in China remains significant but described Huawei as “very, very strong,” adding that local Chinese chip companies are performing well “because we’ve evacuated that market.” Huang also said Huawei likely faces “an extraordinary year coming up.”
Also on May 20, NVIDIA Corporation (NASDAQ:NVDA) reported Q1 adjusted EPS of $1.87, ahead of the consensus estimate of $1.77. Revenue totaled $81.6B, above the consensus estimate of $79.12B. Huang said the buildout of AI factories is “accelerating at extraordinary speed,” while pointing to the rapid scaling of agentic AI across industries. Huang added that Nvidia remains positioned “at the center of this transformation” through its AI infrastructure platform spanning hyperscale data centers and edge deployments.
Following the earnings report, Raymond James raised the firm’s price target on NVIDIA Corporation (NASDAQ:NVDA) to $330 from $323 and maintained a Strong Buy rating on the shares. The firm said Nvidia delivered stronger-than-expected Q1 results and Q2 guidance, driven by inference-led growth and market share gains. Raymond James also highlighted the company’s new $80B buyback authorization and dividend increase from 1c to 25c per share.
NVIDIA Corporation (NASDAQ:NVDA) operates as a data center-scale AI infrastructure company through its Compute & Networking and Graphics segments.
While we acknowledge the potential of NVDA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVDA and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 AI Stocks with Potential to Rise 1000 Percent and 9 Best American Semiconductor Stocks to Buy According to Analysts
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
